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Introduction
The diagnosis of C1 inhibitor (INH) de¢ciency is suspected on the basis of clinical features including recurrent attacks of angioedema and abdominal pain. It is a rare disorder with a prevalence estimated at 1/50,000. The diagnosis is con¢rmed by speci¢c laboratory testing. 1 There are several subtypes of C1 INH de¢ciency including hereditary types I, II and III (HAE), and acquired (AAE). Types 1 and II HAE and AAE are characterized by low C4, although some authors contend that C4 may be normal in rare cases. 2 The very low incidence of the condition makes the sensitivity and speci¢city of assays used particularly important. Two assay approaches to assessing function of C1 INH are available commercially. The ¢rst approach uses chromogenic substrates for activated C1s. The presence of C1 INH inhibits the reaction which may be followed as an endpoint or kinetic reaction. The second allows reaction of C1 INH with C1s before capturing and quantifying the complex. Comparison data on these two approaches are sparse. 3 The study by Spa º th and Wu º thrich 3 reported experience in a large cohort of HAE patients. No direct correlation data were presented, although data were represented longitudinally on several patients. Their data suggested that while both tests are useful in the diagnosis of C1 INH de¢ciency, the C1 INH--C1s complex method is better for monitoring response to therapy.
Comparison data are available from a recently introduced pilot UK National External Quality Assessment Scheme (UK NEQAS). These suggest that the two approaches give very di¡erent results for quanti¢ed C1 INH function.
We compared the performance of these two assays in a well-de¢ned cohort of HAE and AAE patients and non-C1 INH-de¢cient controls.
Methods

C1 inhibitor-C1s complex method
An enzyme immunoassay was used according to the manufacturer's instructions (C1 inhibitor EIA kit, Quidel, San Diego, CA, USA). All analyses were performed in duplicate. In brief, samples were preincubated with biotinylated-C1s. The resulting C1 INH--C1s complex was captured on avidin-coated microtitre plates. Bound complex was detected by horseradish peroxidase-coated anti-human C1 INH. The reference range468% is quoted as normal. After in-house evaluation using probability plotting, 4 this was adjusted to 470%.Within-batch coe⁄cient of variation (CV) was evaluated on normal serum samples (C1 level 130%) repeated 12 times, and was 4%. This compares favourably with the manufacturer's stated within-batch CV of 3--6% at this level. The manufacturer's expected between-batch CV is 11--13%.
Colorimetric method
The Technochrom C1 INH kit was used in endpoint mode according to the manufacturer's instructions (Technoclone GmbH, Vienna, Austria). All analyses were performed in duplicate. In brief, the sample was incubated with excess C1 esterase and the arti¢cial substrate C 2 H 5 CO-lys(e-Cbo)-Gly-Arg-pNA. The amount of colour produced is inversely proportional to the amount of C1 INH present. The reference range is quoted as 70--130%. After in-house evaluation using probability plotting, 4 the lower reference limit was adjusted to 64%. Based on12 repeat analyses, the within-batch CV was estimated as 5%, and between-batch CV 7.8% at a level of 48%.
Patients
This was a cross-sectional study. Seventy-one patients were included in the study (28 HAE, 2 AAE, 41 controls). Cases were de¢ned as previously. 5 In summary, patients were categorized on the basis of their family history (positive in 85% of HAE with 15% representing new mutations), symptom history (recurrent acute oedema of the skin, airways, gastrointestinum or extremities), low immunochemical C1 INH (5--30% of normal in 85% of HAE cases), low C1 INH function when o¡ treatment and low C4 (o30% mean normal) at presentation, as to whether they were likely to have true C1 INH de¢ciency, idiopathic angioedema or other disorders.
The population was drawn from samples stored frozen (À201C) pending analysis. We have shown that samples for C1 INH analysis are stable at À201C for at least two months provided repeated freeze--thawing cycles are carefully avoided (unpublished data). All HAE and AAE patients available at the time of study were included. Controls were drawn from patients who were subsequently shown to have other disorders, predominantly idiopathic angioedema and urticaria. Samples were randomized and analysed blind of other ¢ndings. Table 1 shows a 2 Â2 contingency table of grouped results for chromogenic and C1 INH--C1s complex assays for C1 INH function using the in-house-derived lower reference limits to de¢ne normality. Correspondence was good (65/71; 92%). Six results were discordant. Of these, ¢ve were control patients. Five were low colorimetrically, normal by C1s binding (two HAE 27% and 46%, three controls 44%, 51% and 55%). One control was normal colorimetrically and low by C1s binding (52%).
Results
Linear regression shows modest correlation between the quanti¢ed results (R ¼ 0.81, Figure 1 ). Scatter plots showing quanti¢ed results for each patient group are shown in Figure 2a and 2b for the colorimetric and C1s binding methods, respectively. 
Discussion
The correspondence between the two assays is good (92%). However, the colorimetric assay appears to give some falsely low results in non-HAE patients. We hypothesize that this is most likely a result of sample degradation in transit before storage at À201C. The C1s binding assay appears to be less sensitive to such sample integrity problems.
We have shown that spurious laboratory results may lead to a false diagnosis of HAE. 6 The UK consensus guidelines recommend re-checking the C1 INH by a di¡erent method when the result or diagnosis is in doubt. 1 In the present study, all controls had normal C1 INH by at least one method, which would support this advice.We would also emphasize that in order to make the diagnosis accurately, there is a need for input from an experienced immunologist.
Two HAE patients, in whom analyses by the C1s binding assay were normal, were on treatment. In both these cases the C4 had also normalized on treatment. Spa º th and Wu º thrich 3 noted that the C1s binding method was more sensitive for monitoring therapy than the colorimetric assays.
Resultsp40% mean normal (23 patients by colorimetric assay, 24 patients by C1s binding) were only seen in true C1inhibitor de¢ciency.Thus from the point of view of clinical application, the assays appear to be similarly e¡ective. However, at a practical laboratory level, the need for a pre-incubation step makes the C1s binding assay less amenable to automation.
There is a further problem not addressed by Spa º th and Wu º thrich 3 in that data emanating from the UK NEQAS C1 Inhibitor and Functional Complement Pilot Scheme suggest that the two methods may be di¡erently calibrated, despite similar reference ranges (468% mean normal in the C1 INH--C1s complex method and 70--130% mean normal in the chromogenic method being quoted as normal). Most returns show a bimodal distribution, with the C1 INH--C1s complex method reporting mean results twice that of the chromogenic methods. However, the di¡erence does not seem so marked in our study, suggesting that the more likely explanation is that NEQAS samples undergo £uctuations in transit or in preparation. Colorimetric assays appear to be more sensitive to this than C1s binding assays.
In conclusion, both methods o¡er high sensitivity for HAE, despite di¡erences in the assay principle and reference range. Furthermore, even though there are some discordant results between assays, clinical interpretation of either assay is highly accurate.
